Concord Drugs Limited (BOM:538965)

Concord Drugs Statistics

Total Valuation

Concord Drugs has a market cap or net worth of INR 961.78 million. The enterprise value is 1.15 billion.

Market Cap	961.78M
Enterprise Value	1.15B

Important Dates

The next estimated earnings date is Saturday, February 14, 2026.

Earnings Date	Feb 14, 2026
Ex-Dividend Date	n/a

Share Statistics

Concord Drugs has 13.18 million shares outstanding. The number of shares has decreased by -4.27% in one year.

Current Share Class	13.18M
Shares Outstanding	13.18M
Shares Change (YoY)	-4.27%
Shares Change (QoQ)	+3.24%
Owned by Insiders (%)	69.44%
Owned by Institutions (%)	n/a
Float	4.03M

Valuation Ratios

The trailing PE ratio is 126.21.

PE Ratio	126.21
Forward PE	n/a
PS Ratio	2.13
PB Ratio	2.79
P/TBV Ratio	2.79
P/FCF Ratio	22.75
P/OCF Ratio	14.98
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 25.31, with an EV/FCF ratio of 27.19.

EV / Earnings	199.75
EV / Sales	2.55
EV / EBITDA	25.31
EV / EBIT	37.25
EV / FCF	27.19

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.56.

Current Ratio	1.55
Quick Ratio	0.59
Debt / Equity	0.56
Debt / EBITDA	4.22
Debt / FCF	4.53
Interest Coverage	1.56

Financial Efficiency

Return on equity (ROE) is 1.69% and return on invested capital (ROIC) is 3.29%.

Return on Equity (ROE)	1.69%
Return on Assets (ROA)	2.72%
Return on Invested Capital (ROIC)	3.29%
Return on Capital Employed (ROCE)	7.93%
Weighted Average Cost of Capital (WACC)	6.99%
Revenue Per Employee	1.80M
Profits Per Employee	23,020
Employee Count	250
Asset Turnover	0.64
Inventory Turnover	1.42

Taxes

In the past 12 months, Concord Drugs has paid 4.39 million in taxes.

Income Tax	4.39M
Effective Tax Rate	43.26%

Stock Price Statistics

The stock price has increased by +95.67% in the last 52 weeks. The beta is 0.54, so Concord Drugs's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	+95.67%
50-Day Moving Average	81.81
200-Day Moving Average	58.34
Relative Strength Index (RSI)	36.74
Average Volume (20 Days)	13,241

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Concord Drugs had revenue of INR 450.74 million and earned 5.76 million in profits. Earnings per share was 0.58.

Revenue	450.74M
Gross Profit	94.66M
Operating Income	30.86M
Pretax Income	10.14M
Net Income	5.76M
EBITDA	45.41M
EBIT	30.86M
Earnings Per Share (EPS)	0.58

Balance Sheet

The company has 3.65 million in cash and 191.42 million in debt, with a net cash position of -187.77 million or -14.25 per share.

Cash & Cash Equivalents	3.65M
Total Debt	191.42M
Net Cash	-187.77M
Net Cash Per Share	-14.25
Equity (Book Value)	344.19M
Book Value Per Share	33.99
Working Capital	162.61M

Cash Flow

In the last 12 months, operating cash flow was 64.21 million and capital expenditures -21.93 million, giving a free cash flow of 42.28 million.

Operating Cash Flow	64.21M
Capital Expenditures	-21.93M
Free Cash Flow	42.28M
FCF Per Share	3.21

Margins

Gross margin is 21.00%, with operating and profit margins of 6.85% and 1.28%.

Gross Margin	21.00%
Operating Margin	6.85%
Pretax Margin	2.25%
Profit Margin	1.28%
EBITDA Margin	10.08%
EBIT Margin	6.85%
FCF Margin	9.38%

Dividends & Yields

Concord Drugs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	4.27%
Shareholder Yield	4.27%
Earnings Yield	0.60%
FCF Yield	4.40%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	6